A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
← catalyst calendarNCT03811561 · readout in 445 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,500estimated
Sites
229
Countries
Brazil, Bulgaria, Canada +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-05-08 | actual | When the study began enrolling |
| Primary completion | 2027-11-07 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-07 | estimated | The whole study's end, after follow-up |
| First posted | 2019-01-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 2
Interventions
- Drug: Semaglutide
- Drug: Placebo (semaglutide)
Primary outcome
what the primary-completion date above is the date OFPresence of at least 3 steps Early Treatment Diabetic Retinopathy Study (ETDRS) subject level progression.
measured Year 5
Publications
- PMID 38197991 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed